ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons

FEBS Letters

Volumn 587, Issue 9, 2013, Pages 1316-1325

  Matsui, Hideaki ^a,d   Sato, Fumiaki ^b,d   Sato, Shigeto ^b,d   Koike, Masato ^b   Taruno, Yosuke ^a,d   Saiki, Shinji ^b,d   Funayama, Manabu ^b,d   Ito, Hidefumi ^a,d   Taniguchi, Yoshihito ^a,d   Uemura, Norihito ^a,d   Toyoda, Atsushi ^c   Sakaki, Yoshiyuki ^c   Takeda, Shunichi ^a,d   Uchiyama, Yasuo ^b   Hattori, Nobutaka ^b,d   Takahashi, Ryosuke ^a,d  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

ATP13A2; Lysosome; Medaka fish; Parkinson's disease

Indexed keywords

CATHEPSIN D; CELL PROTEIN; PROTEIN ATP13A2; PROTEIN VARIANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INCLUSION; CELL STRUCTURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; KUFOR RAKEB SYNDROME; LYSOSOME; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NONHUMAN; ORYZIAS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; CATHEPSIN D; CELL LINE, TUMOR; DOPAMINERGIC NEURONS; ENDOPLASMIC RETICULUM; GENE KNOCKDOWN TECHNIQUES; HUMANS; INCLUSION BODIES; LYSOSOMES; MUTATION; ORYZIAS; PROTEIN TRANSPORT; PROTON-TRANSLOCATING ATPASES;

ORYZIINAE;

EID: 84876479782     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.02.046     Document Type: Article

References (38)

1. T. Gasser Update on the genetics of Parkinson's disease Mov. Disord. 22 Suppl. 17 2007 S343 S350
2. A.S. Najim al-Din, A. Wriekat, A. Mubaidin, M. Dasouki, and M. Hiari Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome Acta Neurol. Scand. 89 1994 347 352
3. A. Ramirez, A. Heimbach, J. Gründemann, B. Stiller, D. Hampshire, L.P. Cid, I. Goebel, A.F. Mubaidin, A.L. Wriekat, and J. Roeper Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase Nat. Genet. 38 2006 1184 1191
4. A. Di Fonzo, H.F. Chien, M. Socal, S. Giraudo, C. Tassorelli, G. Iliceto, G. Fabbrini, R. Marconi, E. Fincati, and G. Abbruzzese ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease Neurology 68 2007 1557 1562
5. Y.P. Ning, K. Kanai, H. Tomiyama, Y. Li, M. Funayama, H. Yoshino, S. Sato, M. Asahina, S. Kuwabara, and A. Takeda PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype Neurology 70 2008 1491 1493
6. C. Paisán-Ruiz, R. Guevara, M. Federoff, H. Hanagasi, F. Sina, E. Elahi, S.A. Schneider, P. Schwingenschuh, N. Bajaj, and M. Emre Early-onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations Mov. Disord. 25 2010 1791 1800
7. L. Santoro, G.J. Breedveld, F. Manganelli, R. Iodice, and C. Pisciotta Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability Neurogenetics 12 2011 33 39
8. D. Crosiers, B. Ceulemans, B. Meeus, K. Nuytemans, P. Pals, C. Van Broeckhoven, P. Cras, and J. Theuns Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frame-shift mutation Parkinsonism Relat. Disord. 17 2011 135 138
9. S. Lesage, and A. Brice Parkinson's disease: from monogenic forms to genetic susceptibility factors Hum. Mol. Genet. 18 2009 R48 R59
10. J.P. Covy, E.A. Waxman, and B.I. Giasson Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants J. Neurosci. Res. 90 2012 2306 2316
11. B. Dehay, A. Ramirez, M. Martinez-Vicente, C. Perier, M.H. Canron, E. Doudnikoff, A. Vital, M. Vila, C. Klein, and E.C. Bezard Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration Proc. Natl. Acad. Sci. USA 109 2012 9611 9616
12. A. Podhajska, A. Musso, A. Trancikova, K. Stafa, R. Moser, S. Sonnay, L. Glauser, and D.J. Moore Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism PLoS ONE 7 2012 e39942
13. D. Ramonet, A. Podhajska, K. Stafa, S. Sonnay, A. Trancikova, E. Tsika, O. Pletnikova, J.C. Troncoso, L. Glauser, and D.J. Moore PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity Hum. Mol. Genet. 21 2012 1725 1743
14. M. Usenovic, A.L. Knight, A. Ray, V. Wong, K.R. Brown, G.A. Caldwell, K.A. Caldwell, I. Stagljar, and D. Krainc Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity Hum. Mol. Genet. 21 2012 3785 3794
15. M. Koike, H. Nakanishi, P. Saftig, J. Ezaki, K. Isahara, Y. Ohsawa, W. Schulz-Schaeffer, T. Watanabe, S. Waguri, and S. Kametaka Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons J. Neurosci. 20 2000 6898 6906
16. Y. Taniguchi, S. Takeda, M. Furutani-Seiki, Y. Kamei, T. Todo, T. Sasado, T. Deguchi, H. Kondoh, J. Mudde, and M. Yamazoe Generation of medaka gene knockout models by target-selected mutagenesis Genome Biol. 7 2006 R116
17. H. Matsui, Y. Taniguchi, H. Inoue, K. Uemura, S. Takeda, and R. Takahashi A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish Neurosci. Res. 65 2009 263 271
18. H. Matsui, H. Ito, Y. Taniguchi, H. Inoue, S. Takeda, and R. Takahashi Proteasome inhibition in medaka brain induces the features of Parkinson's disease J. Neurochem. 115 2010 178 187
19. D.N. Palmer, I.M. Fearnley, J.E. Walker, N.A. Hall, B.D. Lake, L.S. Wolfe, M. Haltia, R.D. Martinus, and R.D. Jolly Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease) Am. J. Med. Genet. 42 1992 561 567
20. K. Tsiakas, R. Steinfeld, S. Storch, J. Ezaki, Z. Lukacs, E. Kominami, A. Kohlschütter, K. Ullrich, and T. Braulke Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity Glycobiology 14 2004 1C 5C
21. J. Tyynelä, D.N. Palmer, M. Baumann, and M. Haltia Storage of saposins A and D in infantile neuronal ceroid-lipofuscinosis FEBS Lett. 330 1993 8 12
22. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
23. J.L. Webb, B. Ravikumar, J. Atkins, J.N. Skepper, and D.C. Rubinsztein Alpha-synuclein is degraded by both autophagy and the proteasome J. Biol. Chem. 278 2003 25009 25013
24. D. Narendra, A. Tanaka, D.F. Suen, and R.J. Youle Parkin is recruited selectively to impaired mitochondria and promotes their autophagy J. Cell Biol. 183 2008 795 803
25. J. Tan, T. Zhang, L. Jiang, J. Chi, D. Hu, Q. Pan, D. Wang, and Z. Zhang Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein J. Biol. Chem. 286 2011 29654 29662
26. E. Sidransky, M.A. Nalls, J.O. Aasly, J. Aharon-Peretz, G. Annesi, E.R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, and A. Brice Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease N. Engl. J. Med. 361 2009 1651 1661
27. M. Usenovic, E. Tresse, J.R. Mazzulli, J.P. Taylor, and D. Krainc Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity J. Neurosci. 32 2012 4240 4246
28. E. Siintola, S. Partanen, P. Strömme, A. Haapanen, M. Haltia, J. Maehlen, A.E. Lehesjoki, and J. Tyynelä Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis Brain 129 2006 1438 1445
29. K. Fritchie, E. Siintola, D. Armao, A.E. Lehesjoki, T. Marino, C. Powell, M. Tennison, J.M. Booker, S. Koch, and S. Partanen Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10) Acta Neuropathol. 117 2009 201 208
30. R. Steinfeld, K. Reinhardt, K. Schreiber, M. Hillebrand, R. Kraetzner, W. Bruck, P. Saftig, and J. Gartner Cathepsin D deficiency is associated with a human neurodegenerative disorder Am. J. Hum. Genet. 78 2006 988 998
31. K. Jellinger, A.P. Anzil, D. Seemann, and H. Bernheimer Adult GM2 gangliosidosis masquerading as slowly progressive muscular atrophy: motor neuron disease phenotype Clin. Neuropathol. 1 1982 31 44
32. M.A. Idoate, F.J. Pardo-Mindan, and C. Gonzalez Alamillo Fabry's disease without angiokeratomas showing unusual eccrine gland vacuolation J. Pathol. 167 1992 65 68
33. H. Matsui, Y. Taniguchi, H. Inoue, Y. Kobayashi, Y. Sakaki, A. Toyoda, K. Uemura, D. Kobayashi, S. Takeda, and R. Takahashi Loss of PINK1 in medaka fish (Oryzias latipes) causes late-onset decrease in spontaneous movement Neurosci. Res. 66 2010 151 161
34. H. Matsui, H. Ito, Y. Taniguchi, S. Takeda, and R. Takahashi Ammonium chloride and tunicamycin are novel toxins for dopaminergic neurons and induce Parkinson's disease-like phenotypes in medaka fish J. Neurochem. 115 2010 1150 1160
35. T. Lopes da Fonseca, A. Correia, W. Hasselaar, H.C. van der Linde, R. Willemsen, and T.F. Outeiro The zebrafish homologue of Parkinson's disease ATP13A2 is essential for embryonic survival Brain Res. Bull. 90 2013 118 126
36. A. Barzilai, D. Daily, R. Zilkha-Falb, I. Ziv, D. Offen, E. Melamed, and A. Shirvan The molecular mechanisms of dopamine toxicity Adv. Neurol. 91 2003 73 82
37. S. Gandhi, A. Vaarmann, Z. Yao, M.R. Duchen, N.W. Wood, and A.Y. Abramov Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease PLoS ONE 7 2012 e37564
38. D. Blum, S. Torch, N. Lambeng, M. Nissou, A.L. Benabid, R. Sadoul, and J.M. Verna Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease Prog. Neurobiol. 65 2001 135 172